

# Juan Manuel Sepúlveda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8879917/publications.pdf>

Version: 2024-02-01

73  
papers

2,314  
citations

430874

18  
h-index

233421

45  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3151  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
2	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
3	IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas. <i>Neurotherapeutics</i> , 2022, 19, 408-420.	4.4	2
4	A clinically compatible drug screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14552.	6.9	12
5	Infigratinib in Patients with Recurrent Gliomas and <i>FGFR</i> Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	7.0	30
6	Stratification of radiosensitive brain metastases based on an actionable <i>S100A9</i> /RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	30.7	30
7	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	3.7	8
8	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. <i>Future Science OA</i> , 2022, 8, .	1.9	2
9	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. <i>European Urology Oncology</i> , 2021, 4, 502-505.	5.4	5
10	Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas. <i>Cancer Research</i> , 2021, 81, 2142-2156.	0.9	20
11	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021, 147, 1-12.	2.8	10
12	First-In-Human Phase I Study of a Next-Generation, Oral, TGF $\beta$ 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	7.0	27
13	CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi71-vi72.	1.2	0
14	CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A REVERSIBLE, POTENT ORAL BROMODOMAIN AND EXTRATERMINAL INHIBITOR (BETi) IN PATIENTS WITH HIGH-GRADE GLIOMAS: A PHASE 1 OPEN-LABEL "WINDOW OF OPPORTUNITY" STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi62-vi62.	1.2	0
15	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	2.9	26
16	Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO). <i>Targeted Oncology</i> , 2020, 15, 613-622.	3.6	11
17	Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype. <i>Cancers</i> , 2020, 12, 3230.	3.7	16
18	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805

#	ARTICLE	IF	CITATIONS
19	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	46
20	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	1.2	64
21	Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3514-3514.	1.6	13
22	Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. <i>Scientific Reports</i> , 2019, 9, 11125.	3.3	25
23	Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. <i>PLoS Computational Biology</i> , 2019, 15, e1006778.	3.2	25
24	Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	4.0	16
25	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019, 21, 1263-1272.	1.2	20
26	Morphologic Features on MR Imaging Classify Multifocal Glioblastomas in Different Prognostic Groups. <i>American Journal of Neuroradiology</i> , 2019, 40, 634-640.	2.4	10
27	Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer. <i>Ecancermedalscience</i> , 2019, 13, 891.	1.1	10
28	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019, 21, vi12-vi12.	1.2	3
29	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. <i>Neurocirugia</i> , 2019, 30, 11-18.	0.4	10
30	Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2001-2001.	1.6	6
31	Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2038-2038.	1.6	2
32	Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHIO21).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2613-2613.	1.6	2
33	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi22-vi22.	1.2	0
34	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX-M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE		

#	ARTICLE	IF	CITATIONS
37	Tumor cell vanishing with radiological changes suggesting progression in IDH-mutated diffuse astrocytoma treated only with surgery. , 2018, 37, 217-220.		1
38	CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, TPS4603-TPS4603.	1.6	1
39	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETH1021).. Journal of Clinical Oncology, 2018, 36, TPS3123-TPS3123.	1.6	0
40	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neuro-Oncology Practice, 2017, 4, 15-23.	1.6	6
41	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus, 2017, 3, 280-286.	3.1	2
42	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCulating Endothelial cells) Study (SOGUG-CEC-2011-01). European Urology Focus, 2017, 3, 430-436.	3.1	4
43	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences, 2017, 18, 995.	4.1	32
44	Phase II trial of dacomitinib, a pan-“human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-Oncology, 2017, 19, 1522-1531.	1.2	88
45	Targeting EGFR in Glioblastoma: Molecular Biology and Current Understanding. Current Cancer Research, 2017, , 117-141.	0.2	1
46	Analysis of response rate with anti-PD1/PDL1 antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials (RCT).. Journal of Clinical Oncology, 2017, 35, e14576-e14576.	1.6	4
47	Association of risk of febrile neutropenia (FN) with docetaxel in prostate cancer (PC) patients: A meta-analysis of published phase II-III trials.. Journal of Clinical Oncology, 2017, 35, e21683-e21683.	1.6	0
48	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports, 2016, 18, 66.	4.0	6
49	Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. Neurology, 2016, 87, 114-115.	1.1	3
50	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	2.9	40
51	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1146-1156.	1.2	197
52	RB-independent activity of Cdk4/6 in bladder cancer.. Journal of Clinical Oncology, 2016, 34, e16011-e16011.	1.6	3
53	Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).. Journal of Clinical Oncology, 2016, 34, e17553-e17553.	1.6	1
54	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2016, 34, e16129-e16129.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1548-1558.	4.1	61
56	Cardiac Safety of TGF- $\beta$ Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. <i>Cardiovascular Toxicology</i> , 2015, 15, 309-323.	2.7	74
57	First-in-Human Dose Study of the Novel Transforming Growth Factor- $\beta$ Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	7.0	199
58	A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2014-2014.	1.6	5
59	Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An Oncosur Study Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1029-1029.	1.6	0
60	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11570-e11570.	1.6	1
61	Targeting EGFR in glioblastoma: Preclinical testing of dacomitinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13015-e13015.	1.6	2
62	Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16074-e16074.	1.6	1
63	A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2028-2028.	1.6	0
64	The frequency and impact of ROS1 rearrangement on clinical outcomes in GBM.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2093-2093.	1.6	0
65	Bevacizumab in combination with TMZ in patients with recurrent GBM: Final OS and PFS analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2087-2087.	1.6	1
66	Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single center.. <i>Journal of Clinical Oncology</i> , 2013, 31, 338-338.	1.6	0
67	Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 403-403.	1.6	0
68	Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18558-e18558.	1.6	0
69	The role of pharmacogenomics in metastatic renal cell carcinoma. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 29-32.	5.9	2
70	The oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2042-2042.	1.6	5
71	Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15149-e15149.	1.6	3
72	Prospective exploratory analysis of the association between genetic polymorphisms and sunitinib toxicity and efficacy in metastatic renal-cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4620-4620.	1.6	1

#	ARTICLE	IF	CITATIONS
73	The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab. <i>Oncologist</i> , 2011, 16, 136-145.	3.7	118